Physician profile
Michael E Blam
NPI 1801877733
$2,066.31
in general payments reported to CMS, 2019-2025
11 companies · $656 in 2025
The $656 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $583 · 2021: $134 · 2022: $265 · 2023: $84.35 · 2024: $99.49 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,318.82 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $287.75 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $151.91 | 2021-2024 | Dificid |
| Redhill Biopharma INC. | $62.21 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Janssen Biotech, INC. | $46.97 | 2025 | Tremfya |
| Gilead Sciences, INC. | $38.11 | 2019 | |
| Ferring Pharmaceuticals INC. | $37.49 | 2019-2020 | |
| Abbvie INC. | $36.23 | 2022 | |
| Shield Therapeutics INC | $31.30 | 2024 | |
| Pfizer INC. | $29.43 | 2025 | |
| Madrigal Pharmaceuticals | $26.09 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Blam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.